Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Analgesic Additional Safety Labeling To Be Considered By NDAC

This article was originally published in The Tan Sheet

Executive Summary

Possible new labeling requirements and other initiatives designed to ensure the safety of OTC analgesics will be considered by FDA's Nonprescription Drugs Advisory Committee at a Sept. 19-20 meeting in Silver Spring, Md
Advertisement

Related Content

Ibuprofen Detailed Label Warnings Necessity Questioned By Wyeth
Ibuprofen Detailed Label Warnings Necessity Questioned By Wyeth
Ibuprofen Detailed Label Warnings Necessity Questioned By Wyeth
Naproxen Directly Linked To GI Bleeding In 32% Of Cases Reviewed By FDA
Ibuprofen Detailed Renal, GI Warnings Required For Monograph Inclusion
OTC Analgesic Toxicity Review Expected By Fall – FDA
OTC Analgesic Toxicity Review Expected By Fall – FDA
Acetaminophen, Aspirin Not Linked To Kidney Disease Risk - JAMA Study
UK Acetaminophen Deaths Decline 21% After Packaging Changes
OTC Acetaminophen Access Limitations To Be Considered By FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS094279

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel